Northwest Biotherapeutics Inc financial data

Symbol
NWBO on OTC
Industry
Pharmaceutical Preparations
Location
4800 Montgomery Lane, Suite 800, Bethesda, MD
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 10.6 % -2.31%
Debt-to-equity -111 % -0.4%
Return On Equity 105 % +7.74%
Return On Assets -254 % +9%
Operating Margin -4.36K % -38.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.25B shares +11.3%
Common Stock, Shares, Outstanding 1.23B shares +10.3%
Entity Public Float 617M USD 0%
Common Stock, Value, Issued 1.23M USD +10.2%
Weighted Average Number of Shares Outstanding, Basic 1.21M shares +9.55%
Weighted Average Number of Shares Outstanding, Diluted 1.21M shares +9.55%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 1.34M USD -38.1%
Revenue from Contract with Customer, Excluding Assessed Tax 510K USD +154%
Research and Development Expense 30.9M USD +2.55%
General and Administrative Expense 32.9M USD +2.59%
Operating Income (Loss) -62.2M USD -3.05%
Net Income (Loss) Attributable to Parent -73.7M USD +14.6%
Earnings Per Share, Basic -0.08 USD/shares +20%
Earnings Per Share, Diluted -0.08 USD/shares +20%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 2.88M USD +102%
Assets, Current 4.98M USD +7.2%
Property, Plant and Equipment, Net 17M USD -1.87%
Operating Lease, Right-of-Use Asset 4M USD -5.53%
Goodwill 626K USD 0%
Other Assets, Noncurrent 372K USD +3.05%
Assets 28.2M USD -0.75%
Liabilities, Current 56.2M USD +40.7%
Operating Lease, Liability, Noncurrent 4.36M USD -0.18%
Liabilities 86M USD +34.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax 2.22M USD +17.5%
Retained Earnings (Accumulated Deficit) -1.4B USD -5.57%
Stockholders' Equity Attributable to Parent -76.5M USD -25.3%
Liabilities and Equity 28.2M USD -0.75%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -12.4M USD -10.4%
Net Cash Provided by (Used in) Financing Activities 12.1M USD -3.95%
Net Cash Provided by (Used in) Investing Activities -239K USD +82.1%
Common Stock, Shares Authorized 1.7B shares 0%
Common Stock, Shares, Issued 1.23B shares +10.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 352K USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 2.88M USD +102%
Deferred Tax Assets, Valuation Allowance 261M USD +5.56%
Deferred Tax Assets, Gross 261M USD +5.56%
Operating Lease, Liability 4.54M USD -4.59%
Depreciation 400K USD +33.3%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -75.2M USD +15.3%
Lessee, Operating Lease, Liability, to be Paid 9.57M USD -5.74%
Operating Lease, Liability, Current 175K USD -54.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 658K USD +3.95%
Lessee, Operating Lease, Liability, to be Paid, Year One 658K USD -21.5%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 5.03M USD -6.76%
Lessee, Operating Lease, Liability, to be Paid, Year Three 658K USD +3.95%
Deferred Tax Assets, Operating Loss Carryforwards 212M USD +4.45%
Preferred Stock, Shares Authorized 100M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 658K USD +3.95%
Operating Lease, Payments 241K USD +7.11%
Share-based Payment Arrangement, Expense 5.49M USD -23%
Interest Expense 5.73M USD +10.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%